Deprenyl, excess mortality, and epidemiological traps

Clinical Neuropharmacology

Volumn 20, Issue 3, 1997, Pages 276-278

  Riggs, Jack E ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Age matching; Deprenyl; Epidemiology; Mortality; Parkinson's disease

Indexed keywords

SELEGILINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; MALE; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030953123     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199706000-00013     Document Type: Article

References (3)

1. Lee AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995;311:1602-7.
2. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993;307:469-72.
3. Riggs JE. The dynamics of aging and mortality in the United States, 1900-1988. Mech Aging Dev 1992;66:45-57.